{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:44:24Z","timestamp":1784040264763,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The aims of the study were to evaluate potential differences among first-line treatment for <jats:italic>EGFR<\/jats:italic> mutant (m+) non-small cell lung cancer (NSCLC) patients with brain metastasis in China and to identify the factors influencing survival outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective study, 172 <jats:italic>EGFR<\/jats:italic>m\u2009+\u2009patients with advanced NSCLC who received a 1st generation EGFR tyrosine kinase inhibitor (TKI) were divided into 4 groups: A, EGFR-TKI (n\u2009=\u200984); B, EGFR-TKI\u2009+\u2009pemetrexed\u2009+\u2009cisplatin\/carboplatin chemotherapy (CT) (n\u2009=\u200955); C, EGFR-TKI\u2009+\u2009bevacizumab (n\u2009=\u200915); and D, EGFR-TKI\u2009+\u2009pemetrexed\u2009+\u2009cisplatin\/carboplatin CT\u2009+\u2009bevacizumab (n\u2009=\u200918). Intracranial and extracranial progression-free survival (PFS), the overall survival (OS), objective remission rates (ORRs) and adverse events were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Intracranial PFS of groups C\u2009+\u2009D was longer than for groups A\u2009+\u2009B (18.9\u00a0m vs. 11.0\u00a0m, <jats:italic>P<\/jats:italic>\u2009=\u20090.027). Extracranial PFS were longer in group B in comparison with group A (13.0\u00a0m vs. 11.5\u00a0m, <jats:italic>P<\/jats:italic>\u2009=\u20090.039) and in groups C\u2009+\u2009D compared to groups A\u2009+\u2009B (18.9\u00a0m vs. 11.9\u00a0m, <jats:italic>P<\/jats:italic>\u2009=\u20090.008). Median OS in groups A and B were 27.9\u00a0m and 24.4\u00a0m, respectively, while groups C and D have not yet achieved median OS. Significant difference was found in intracranial ORR between groups A\u2009+\u2009B vs. C\u2009+\u2009D (31.0% vs. 65.2%, <jats:italic>P<\/jats:italic>\u2009=\u20090.002). Most patients suffered grade 1\u20132 treatment-related adverse events, which were relieved soon after symptomatic treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>First-generation EGFR-TKI\u2009+\u2009bevacizumab treatment outperformed other regimens in <jats:italic>EGFR<\/jats:italic>m\u2009+\u2009NSCLC patients with brain metastasis. The therapy improved the control and delayed progression of intracranial lesions and prolonged survival times.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-023-10744-2","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T08:06:16Z","timestamp":1680163576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study"],"prefix":"10.1186","volume":"23","author":[{"given":"Huijuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyue","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangtao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"issue":"5","key":"10744_CR1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/PPO.0000000000000146","volume":"21","author":"SB Goldberg","year":"2015","unstructured":"Goldberg SB, Contessa JN, Omay SB, Chiang V. Lung Cancer Brain Metastases. Cancer J. 2015;21(5):398\u2013403.","journal-title":"Cancer J"},{"issue":"1","key":"10744_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1515\/med-2020-0192","volume":"15","author":"P Liang","year":"2020","unstructured":"Liang P, Wang YD, Wei ZM, Deng QJ, Xu T, Liu J, et al. Bevacizumab for non-small cell lung cancer patients with brain metastasis: a meta-analysis. Open Med (Wars). 2020;15(1):589\u201397.","journal-title":"Open Med (Wars)"},{"issue":"5","key":"10744_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5732\/cjc.011.10106","volume":"30","author":"W Zhou","year":"2011","unstructured":"Zhou W, Christiani DC. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer. 2011;30(5):287\u201392.","journal-title":"Chin J Cancer"},{"key":"10744_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3389\/fonc.2018.00208","volume":"8","author":"WJ Kelly","year":"2018","unstructured":"Kelly WJ, Shah NJ, Subramaniam DS. Management of brain metastases in epidermal growth factor receptor mutant non-small-cell Lung Cancer. Front Oncol. 2018;8:208.","journal-title":"Front Oncol"},{"issue":"11","key":"10744_CR5","doi-asserted-by":"publisher","first-page":"e0143515","DOI":"10.1371\/journal.pone.0143515","volume":"10","author":"Y Shi","year":"2015","unstructured":"Shi Y, Li J, Zhang S, Wang M, Yang S, Li N, et al. Molecular Epidemiology of EGFR mutations in asian patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. PLoS ONE. 2015;10(11):e0143515.","journal-title":"PLoS ONE"},{"issue":"2","key":"10744_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11060-017-2590-x","volume":"135","author":"M Ge","year":"2017","unstructured":"Ge M, Zhuang Y, Zhou X, Huang R, Liang X, Zhan Q. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases. J Neurooncol. 2017;135(2):413\u20138.","journal-title":"J Neurooncol"},{"issue":"11","key":"10744_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1200\/JOP.19.00357","volume":"15","author":"V Ernani","year":"2019","unstructured":"Ernani V, Stinchcombe TE. Management of Brain Metastases in Non-Small-Cell Lung Cancer. J Oncol Pract. 2019;15(11):563\u201370.","journal-title":"J Oncol Pract"},{"key":"10744_CR8","doi-asserted-by":"crossref","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A et al. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.J Clin Oncol. 2018:JCO2018783118.","DOI":"10.1200\/JCO.2018.78.3118"},{"issue":"26","key":"10744_CR9","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","volume":"36","author":"YL Wu","year":"2018","unstructured":"Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, et al. CNS efficacy of Osimertinib in patients with T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data from a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018;36(26):2702\u20139.","journal-title":"J Clin Oncol"},{"key":"10744_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137.","journal-title":"Eur J Cancer"},{"issue":"12","key":"10744_CR11","doi-asserted-by":"publisher","first-page":"e1417","DOI":"10.1634\/theoncologist.2019-0152","volume":"24","author":"JH Lee","year":"2019","unstructured":"Lee JH, Chen HY, Hsu FM, Chen JS, Liao WY, Shih JY, et al. Cranial irradiation for patients with epidermal growth factor receptor (EGFR) Mutant Lung Cancer who have brain metastases in the era of a New Generation of EGFR inhibitors. Oncologist. 2019;24(12):e1417\u2013e25.","journal-title":"Oncologist"},{"issue":"10","key":"10744_CR12","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.jtho.2016.06.002","volume":"11","author":"J Khalifa","year":"2016","unstructured":"Khalifa J, Amini A, Popat S, Gaspar LE, Faivre-Finn C. International Association for the study of Lung Cancer Advanced Radiation Technology C. Brain Metastases from NSCLC: Radiation Therapy in the era of targeted therapies. J Thorac Oncol. 2016;11(10):1627\u201343.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10744_CR13","first-page":"36","volume":"4","author":"BA Chan","year":"2015","unstructured":"Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36\u201354.","journal-title":"Transl Lung Cancer Res"},{"issue":"25","key":"10744_CR14","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"10744_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239\u201346.","journal-title":"Lancet Oncol"},{"issue":"2","key":"10744_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","volume":"38","author":"Y Hosomi","year":"2020","unstructured":"Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, et al. Gefitinib alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020;38(2):115\u201323.","journal-title":"J Clin Oncol"},{"issue":"27","key":"10744_CR17","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1200\/JCO.2016.66.9218","volume":"34","author":"Y Cheng","year":"2016","unstructured":"Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, et al. Randomized phase II trial of Gefitinib with and without pemetrexed as first-line therapy in patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016;34(27):3258\u201366.","journal-title":"J Clin Oncol"},{"issue":"11","key":"10744_CR18","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1158\/1078-0432.CCR-06-2923","volume":"13","author":"T Li","year":"2007","unstructured":"Li T, Ling YH, Goldman ID, Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res. 2007;13(11):3413\u201322.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10744_CR19","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1158\/1078-0432.CCR-08-2407","volume":"15","author":"N Schicher","year":"2009","unstructured":"Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, et al. Erlotinib and Bevacizumab have synergistic activity against Melanoma. Clin Cancer Res. 2009;15(10):3495.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10744_CR20","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/14728222.2017.1371137","volume":"21","author":"D Frezzetti","year":"2017","unstructured":"Frezzetti D, Gallo M, Maiello MR, D\u2019Alessio A, Esposito C, Chicchinelli N, et al. VEGF as a potential target in lung cancer. Expert Opin Ther Targets. 2017;21(10):959\u201366.","journal-title":"Expert Opin Ther Targets"},{"issue":"12","key":"10744_CR21","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","volume":"13","author":"HL Goel","year":"2013","unstructured":"Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871\u201382.","journal-title":"Nat Rev Cancer"},{"issue":"6382","key":"10744_CR22","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"5","key":"10744_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S2213-2600(17)30129-7","volume":"5","author":"R Rosell","year":"2017","unstructured":"Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017;5(5):435\u201344.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10744_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","volume":"20","author":"H Saito","year":"2019","unstructured":"Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625\u201335.","journal-title":"Lancet Oncol"},{"issue":"11","key":"10744_CR25","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","volume":"15","author":"T Seto","year":"2014","unstructured":"Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236\u201344.","journal-title":"Lancet Oncol"},{"issue":"8","key":"10744_CR26","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-14-2082","volume":"21","author":"B Besse","year":"2015","unstructured":"Besse B, Le Moulec S, Mazieres J, Senellart H, Barlesi F, Chouaid C, et al. Bevacizumab in patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, untreated brain metastases (BRAIN): a Nonrandomized, phase II study. Clin Cancer Res. 2015;21(8):1896\u2013903.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10744_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.21037\/atm.2018.09.33","volume":"6","author":"Y Chikaishi","year":"2018","unstructured":"Chikaishi Y, Kanayama M, Taira A, Nabe Y, Shinohara S, Kuwata T, et al. Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer. Ann Transl Med. 2018;6(20):401.","journal-title":"Ann Transl Med"},{"issue":"7","key":"10744_CR28","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jtho.2018.03.032","volume":"13","author":"PH Feng","year":"2018","unstructured":"Feng PH, Chen KY, Huang YC, Luo CS, Wu SM, Chen TT, et al. Bevacizumab reduces S100A9-Positive MDSCs linked to Intracranial Control in patients with EGFR-Mutant Lung Adenocarcinoma. J Thorac Oncol. 2018;13(7):958\u201367.","journal-title":"J Thorac Oncol"},{"key":"10744_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejca.2019.08.021","volume":"121","author":"T Jiang","year":"2019","unstructured":"Jiang T, Zhang Y, Li X, Zhao C, Chen X, Su C, et al. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases. Eur J Cancer. 2019;121:98\u2013108.","journal-title":"Eur J Cancer"},{"issue":"34","key":"10744_CR30","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1200\/JCO.2012.47.9626","volume":"31","author":"JD Patel","year":"2013","unstructured":"Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(34):4349\u201357.","journal-title":"J Clin Oncol"},{"issue":"26","key":"10744_CR31","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1200\/JCO.19.01006","volume":"37","author":"SS Ramalingam","year":"2019","unstructured":"Ramalingam SS, Dahlberg SE, Belani CP, Saltzman JN, Pennell NA, Nambudiri GS, et al. Pemetrexed, Bevacizumab, or the combination as maintenance therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. J Clin Oncol. 2019;37(26):2360\u20137.","journal-title":"J Clin Oncol"},{"issue":"7","key":"10744_CR32","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jamaoncol.2020.1260","volume":"6","author":"HA Yu","year":"2020","unstructured":"Yu HA, Schoenfeld AJ, Makhnin A, Kim R, Rizvi H, Tsui D, et al. Effect of Osimertinib and Bevacizumab on Progression-Free Survival for patients with metastatic EGFR-Mutant lung cancers: a phase 1\/2 single-group open-label trial. JAMA Oncol. 2020;6(7):1048\u201354.","journal-title":"JAMA Oncol"},{"issue":"2","key":"10744_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.annonc.2021.11.010","volume":"33","author":"RA Soo","year":"2022","unstructured":"Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, et al. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the european thoracic oncology platform (ETOP 10\u201316) BOOSTER trial. Ann Oncol. 2022;33(2):181\u201392.","journal-title":"Ann Oncol"},{"issue":"3","key":"10744_CR34","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamaoncol.2020.6758","volume":"7","author":"H Akamatsu","year":"2021","unstructured":"Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, et al. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in patients with EGFR T790M-Mutated Non-Small Cell Lung Cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor: West Japan Oncology Group 8715L phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(3):386\u201394.","journal-title":"JAMA Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-10744-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-10744-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-10744-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T08:09:25Z","timestamp":1680163765000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-10744-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["10744"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-10744-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"3 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital and was conducted strictly following the Declaration of Helsinki of the World Medical Association guidelines. The need for written informed consent was waived by the ethics committee of The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"289"}}